A randomized phase 2b trial found that intravenous zabilugene almadenorepvec (VCN-01) combined with gemcitabine and nab-paclitaxel prolonged overall survival in treatment-naive metastatic pancreatic cancer compared with chemotherapy alone.
Oncolytic Virus Plus Chemotherapy Extends Survival in Metastatic Pancreatic Cancer
A randomized phase 2b trial found that intravenous zabilugene almadenorepvec (VCN-01) combined with gemcitabine and nab-paclitaxel prolonged overall survival in treatment-naive metastatic pancreatic cancer compared with chemotherapy alone.
Pancreatic cancer · Wikimedia — licence per file · rights
This item was produced with AI assistance under the editorial responsibility of Haydamax OÜ.
Monitoring item. The full text is not distributed. Extract and source below.